News & Articles

Vanderbilt researchers use high-throughput data collection, analysis, and visualization to help understand synergy in therapeutic antibody cocktails

Join us on Wednesday, August 26, to learn about an alternative assay that aims to identify virus-neutralizing antibodies in as little as five hours

BLENREP is the fifth major medicine approval for GSK in 2020

Just leave a quick lab product review today for your chance to scoop one of our weekly $100 prizes

With this numerical result expressed as index value, clinicians will be better equipped to evaluate the duration and level of an individual’s immune response

Ideal for cell and gene therapy and COVID-19 research, BioStore IIIv offers inventory control and reporting capabilities

The modular solution aims to deliver test results in a four-step process requiring minimal hands-on time, laboratory space and staffing resources

Exclusive interviews, new methods, free downloads, and much more to help you advance your work

California Laboratories can now instantly transmit covid-19 data to the CalREDIE system

Dr. Nallasivam Palanisamy, Henry Ford Cancer Institute, discusses his discovery of the first pseudogene-associated recurrent gene fusion in cancer and the potential for this robust biomarker for application beyond prostate cancer

Watch this on-demand webinar to discover how pancreatic cancer-derived organoids can be used as a predictive tool for personalized medicine

Rapid antibody test receives CE mark for use by healthcare professionals

University of California San Francisco (UCSF) uses Phenoptics™ platform to help with biomarker discovery

TrueBinding signs multi-product commercial-use license to develop stable, antibody-expressing cell lines using Horizon’s gene-edited CHO GS knockout platform

87 percent of patients in ZUMA-2 pivotal trial responded to single infusion of Tecartus

Developed with enhanced technology, this new assay provides high-quality staining with improved turnaround time

New platform provides faster identification of defects that impact device performance

Leading clinical scientists and health professionals have come together to discuss the latest diagnostic and point-of-care solutions at this critical time

The study is the first global, randomized, double-blind, placebo-controlled phase III trial investigating Actemra/RoActemra in this setting